Will the promise of drug-induced therapeutic hypothermia be fulfilled?

Crit Care Med. 2014 Jan;42(1):221-3. doi: 10.1097/CCM.0b013e3182a12275.

Authors

Maximilian Mulder¹, Romergryko G Geocadin

Affiliation

¹ Department of Neurology, Department of Anesthesia and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD Department of Neurology, Department of Anesthesia and Critical Care Medicine, Department of Neurosurgery, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.

PMID: 24346538
DOI: 10.1097/CCM.0b013e3182a12275

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural
Comment

MeSH terms

Animals
Benzoxazines / therapeutic use*
Brain / physiopathology*
Cannabinoid Receptor Agonists / therapeutic use*
Cardiopulmonary Resuscitation / methods*
Heart / physiopathology*
Heart Arrest / drug therapy*
Hypothermia, Induced / methods*
Male
Morpholines / therapeutic use*
Naphthalenes / therapeutic use*

Substances

Benzoxazines
Cannabinoid Receptor Agonists
Morpholines
Naphthalenes
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone

Grants and funding